MannKind | MNKD - Current Liabilities


MannKind reported $109.13M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Adma Biologics USD 56.49M 18.45M Sep/2025
Dynavax Technologies USD 106.84M 11.39M Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Halozyme Therapeutics USD 837.23M 702.95M Sep/2025
Insmed USD 417.21M 105.53M Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
MannKind USD 109.13M 2.7M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Novo Nordisk DKK 32.79B 203.33B Jun/2025
Pfizer USD 36.6B 1.13B Sep/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Xencor USD 86.48M 9.6M Sep/2025